Prime‐boost vaccinations using recombinant flavivirus replicon and vaccinia virus vaccines: an ELISPOT analysis

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Immunology and Cell Biology

• Publication date

  2011-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/icb.2010.99PMID 20680025
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Addendum: Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge

  2011cited by this paper
• Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine

  2010cited by this paper
• Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens.

  2010cited by this paper
• Reciprocal responsiveness to interleukin-12 and interferon-alpha specifies human CD8+ effector versus central memory T-cell fates.

  2009cited by this paper
• The precursors of memory: models and controversies

  2009cited by this paper
• Effector-memory T cell responses are associated with protection of rhesus monkeys from mucosal SIV challenge

  2009cited by this paper
• Immunostimulatory cancer chemotherapy using local ingenol-3-angelate and synergy with immunotherapies.

  2009cited by this paper
• Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity.

  2009cited by this paper
• The role of IFN-γ Elispot assay in HIV vaccine research

  2009cited by this paper
• Surviving the crash: transitioning from effector to memory CD8+ T cell.

  2009cited by this paper
• Broad, high-magnitude and multifunctional CD4+ and CD8+ T-cell responses elicited by a DNA and modified vaccinia Ankara vaccine containing human immunodeficiency virus type 1 subtype C genes in baboons.

  2009cited by this paper
• Prime-boost vaccination with a fowlpox vector and an inactivated avian influenza vaccine is highly immunogenic in Pekin ducks challenged with Asian H5N1 HPAI.

  2009cited by this paper
• The relationship between human effector and memory T cells measured by ex vivo and cultured ELISPOT following recent and distal priming

  2009cited by this paper
• Japanese encephalitis virus-based replicon RNAs/particles as an expression system for HIV-1 Pr55 Gag that is capable of producing virus-like particles.

  2009cited by this paper
• Protective Efficacy of a Single Immunization of a Chimeric Adenovirus Vector-Based Vaccine against Simian Immunodeficiency Virus Challenge in Rhesus Monkeys

  2009cited by this paper
• Prime-boost immunization using alphavirus replicon and adenovirus vectored vaccines induces enhanced immune responses against classical swine fever virus in mice.

  2009cited by this paper
• Genetic heterologous prime–boost vaccination strategies for improved systemic and mucosal immunity

  2009cited by this paper
• Heterologous prime–boost vaccinations for poverty-related diseases: advantages and future prospects

  2009cited by this paper
• Heterologous prime-boost vaccination.

  2009cited by this paper
• Type I interferons as vaccine adjuvants against infectious diseases and cancer

  2008cited by this paper
• Therapeutic and prophylactic applications of alphavirus vectors

  2008cited by this paper
• Primer: making sense of T-cell memory

  2008cited by this paper
• Kunjin replicon-based simian immunodeficiency virus gag vaccines

  2008cited by this paper
• A Multigene HIV Type 1 Subtype C Modified Vaccinia Ankara (MVA) Vaccine Efficiently Boosts Immune Responses to a DNA Vaccine in Mice

  2008cited by this paper
• An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses

  2008cited by this paper
• Heterologous prime-boost immunotherapy of melanoma patients with Influenza virosomes, and recombinant Vaccinia virus encoding 5 melanoma epitopes and 3 co-stimulatory molecules. A multi-centre phase I/II open labeled clinical trial.

  2008cited by this paper
• DNA vaccines: ready for prime time?

  2008cited by this paper
• Special Anniversary Review: Twenty-five years of human immunodeficiency virus research: successes and challenges

  2008cited by this paper
• Memory CD8+ T Cell Responses Expand When Antigen Presentation Overcomes T Cell Self-Regulation1

  2008cited by this paper
• Vaccination with a Modified Vaccinia Virus Ankara‐based vaccine protects mice from allergic sensitization

  2008cited by this paper
• The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer.

  2008cited by this paper
• Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response.

  2008cited by this paper
• Shaping and reshaping CD8+ T-cell memory

  2008cited by this paper
• Comparison of multiple vaccine vectors in a single heterologous prime-boost trial.

  2008cited by this paper
• DNA gag/Adenovirus Type 5 (Ad5) gag and Ad5 gag/Ad5 gag Vaccines Induce Distinct T-Cell Response Profiles

  2008cited by this paper
• Heterologous Prime/Boost Immunization of Rhesus Monkeys by Using Diverse Poxvirus Vectors

  2007cited by this paper
• Comparative Prime-Boost Vaccinations Using Semliki Forest Virus, Adenovirus, and ALVAC Vectors Demonstrate Differences in the Generation of a Protective Central Memory CTL Response against the P815 Tumor1

  2007cited by this paper
• A Heterologous DNA Prime-Venezuelan Equine Encephalitis Virus Replicon Particle Boost Dengue Vaccine Regimen Affords Complete Protection from Virus Challenge in Cynomolgus Macaques

  2007cited by this paper
• A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice.

  2007cited by this paper
• HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3.

  2007cited by this paper
• Immunodominance and immunodomination: critical factors in developing effective CD8+ T-cell-based cancer vaccines.

  2006cited by this paper
• Programming, demarcating, and manipulating CD8+ T‐cell memory

  2006cited by this paper
• Progress and obstacles in the development of an AIDS vaccine

  2006cited by this paper
• DNA vaccines for allergy treatment.

  2006cited by this paper
• Different Levels of Immunogenicity of Two Strains of Fowlpox Virus as Recombinant Vaccine Vectors Eliciting T-Cell Responses in Heterologous Prime-Boost Vaccination Strategies

  2006cited by this paper
• Poxvirus CD8+ T-Cell Determinants and Cross-Reactivity in BALB/c Mice

  2006cited by this paper
• Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis.

  2006cited by this paper
• Comparative Efficacy of Subtype AE Simian-Human Immunodeficiency Virus Priming and Boosting Vaccines in Pigtail Macaques

  2006cited by this paper
• Virus-Specific Cellular Immune Correlates of Survival in Vaccinated Monkeys after Simian Immunodeficiency Virus Challenge

  2006cited by this paper
• Type I Interferons are essential for the efficacy of replicase-based DNA vaccines.

  2006cited by this paper
• Kunjin virus replicons: an RNA-based, non-cytopathic viral vector system for protein production, vaccine and gene therapy applications

  2006cited by this paper
• Induction of Multifunctional Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T Cells Capable of Proliferation in Healthy Subjects by Using a Prime-Boost Regimen of DNA- and Modified Vaccinia Virus Ankara-Vectored Vaccines Expressing HIV-1 Gag Coupled to CD8+ T-Cell Epitopes

  2006cited by this paper
• Vaccine-Induced CD8+ Central Memory T Cells in Protection from Simian AIDS

  2005cited by this paper
• Differential Immunogenicity of Various Heterologous Prime-Boost Vaccine Regimens Using DNA and Viral Vectors in Healthy Volunteers1

  2005cited by this paper
• From mice to humans – murine intelligence for human CD8+ T cell vaccine design

  2005cited by this paper
• Enhanced CD8+ T Cell Immune Responses and Protection Elicited against Plasmodium berghei Malaria by Prime Boost Immunization Regimens Using a Novel Attenuated Fowlpox Virus1

  2004cited by this paper
• Vaccine protection from CD4+ T-cell loss caused by simian immunodeficiency virus (SIV) mac251 is afforded by sequential immunization with three unrelated vaccine vectors encoding multiple SIV antigens.

  2004cited by this paper
• Modified‐vaccinia‐virus‐ankara (MVA) priming and fowlpox‐virus booster elicit a stronger CD8+ T‐cell response in mice against an HIV‐1 epitope than does a DNA/poxvirus prime‐booster approach

  2004cited by this paper
• DNA/MVA Vaccine for HIV Type 1: Effects of Codon-Optimization and the Expression of Aggregates or Virus-Like Particles on the Immunogenicity of the DNA Prime

  2004cited by this paper
• Efficacy of DNA and Fowlpox Virus Priming/Boosting Vaccines for Simian/Human Immunodeficiency Virus

  2004cited by this paper
• Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal simian immunodeficiency virus challenge.

  2004cited by this paper
• Tetracycline-Inducible Packaging Cell Line for Production of Flavivirus Replicon Particles

  2004cited by this paper
• DNA vaccines for allergy treatment.

  2004cited by this paper
• Jump-starting the immune system: prime-boosting comes of age.

  2004cited by this paper
• A Consecutive Priming-Boosting Vaccination of Mice with Simian Immunodeficiency Virus (SIV) gag/pol DNA and Recombinant Vaccinia Virus Strain DIs Elicits Effective Anti-SIV Immunity

  2004cited by this paper
• Induction of Broad and Potent Anti-Human Immunodeficiency Virus Immune Responses in Rhesus Macaques by Priming with a DNA Vaccine and Boosting with Protein-Adsorbed Polylactide Coglycolide Microparticles

  2003cited by this paper
• Boosting with recombinant vaccinia increases HPV-16 E7-Specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles.

  2003cited by this paper
• Prior DNA immunization enhances immune response to dominant and subdominant viral epitopes induced by a fowlpox-based SIVmac vaccine in long-term slow-progressor macaques infected with SIVmac251.

  2003cited by this paper
• Prime Boost Vaccination Strategies: CD8 T Cell Numbers, Protection, and Th1 Bias1

  2003cited by this paper
• Kunjin Virus Replicon Vaccine Vectors Induce Protective CD8+ T-Cell Immunity

  2002cited by this paper
• Competition Between CTL Narrows the Immune Response Induced by Prime-Boost Vaccination Protocols1

  2002cited by this paper
• Recombinant Vaccinia Virus-Induced T-Cell Immunity: Quantitation of the Response to the Virus Vector and the Foreign Epitope

  2002cited by this paper
• Different Patterns of Immune Responses but Similar Control of a Simian-Human Immunodeficiency Virus 89.6P Mucosal Challenge by Modified Vaccinia Virus Ankara (MVA) and DNA/MVA Vaccines

  2002cited by this paper
• Replicon-based vectors of positive strand RNA viruses.

  2000cited by this paper
• Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity.

  1999cited by this paper
• Induction of CD8+ T cells using heterologous prime‐boost immunisation strategies

  1999cited by this paper
• Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination.

  1998cited by this paper
• Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes.

  1996cited by this paper
• Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design.

  1995cited by this paper

• Replicon RNA vaccines: design, delivery, and immunogenicity in infectious diseases and cancer

  2025cites this paper
• A vaccinia-based single vector construct multi-pathogen vaccine protects against both Zika and chikungunya viruses

  2018cites this paper
• Basic Vaccine Immunology

  2016cites this paper
• Development of the S3Pvac Vaccine Against Murine Taenia crassiceps Cysticercosis: A Historical Review

  2013cites this paper
• A DNA-based West Nile virus replicon elicits humoral and cellular immune responses in mice.

  2011cites this paper